[HTML][HTML] Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study
FX Mahon, D Rea, J Guilhot, F Guilhot, F Huguet… - Blood, 2011 - Elsevier
Abstract Abstract 603 Background: Imatinib treatment significantly improves survival in
patients (pts) with CML. We previously demonstrated that Imatinib could be safely …
patients (pts) with CML. We previously demonstrated that Imatinib could be safely …
Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: interim analysis of the STIM trial
F Mahon FX, D Rea, F Guilhot, L Legros… - Journal of Clinical …, 2009 - ascopubs.org
7084 Background: Imatinib (IM) has greatly improved survival in chronic myeloid leukemia
(CML). However, IM must be continued for an indefinite period of time. A multicenter trial …
(CML). However, IM must be continued for an indefinite period of time. A multicenter trial …
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …
FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
[HTML][HTML] Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients.
FX Mahon, D Rea, F Guilhot, F Huguet, FE Nicolini… - Blood, 2009 - Elsevier
Abstract Abstract 859 Background Imatinib (IM) has greatly improved survival rates in
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …
[HTML][HTML] Discontinuation of imatinib in patients with CML and sustained complete molecular response (CMR) for over 2 years in the Japanese population–an interim …
E Matsuki, Y Ono, M Sakurai, H Kunimoto, J Ishizawa… - Blood, 2011 - Elsevier
Abstract Abstract 3765 Background: The introduction of imatinib mesylate in the treatment of
chronic myeloid leukemia (CML) has dramatically changed its treatment outcome. The drug …
chronic myeloid leukemia (CML) has dramatically changed its treatment outcome. The drug …
[HTML][HTML] Long-term follow-up of the French 1 Stop Imatinib Study (STIM1) in chronic myeloid leukemia patients
G Etienne, D Rea, J Guilhot, F Guilhot, F Huguet… - Blood, 2015 - Elsevier
Background We previously demonstrated that Imatinib (IM) could be safely discontinued in
patients with undetectable minimal residual disease (UMRD) of at least 2 years (Lancet …
patients with undetectable minimal residual disease (UMRD) of at least 2 years (Lancet …
[HTML][HTML] Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French Pilot Study and first results from the multicentre «Stop …
FX Mahon, F Huguet, F Guilhot, L Legros, FE Nicolini… - Blood, 2008 - Elsevier
Imatinib (IM) has greatly improved survival rates in chronic myeloid leukemia (CML).
However, all patients (pts) must continue treatment for an unknown period of time. A pilot …
However, all patients (pts) must continue treatment for an unknown period of time. A pilot …
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia …
N Takahashi, T Tauchi, K Kitamura, K Miyamura… - International journal of …, 2018 - Springer
The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
[HTML][HTML] Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib
FX Mahon, FE Nicolini, MP Noël, M Escoffre… - Blood, 2013 - Elsevier
Abstract Background In the Stop imatinib study (STIM) 1, we previously demonstrated that
Imatinib could be safely discontinued in patients with a sustained deep molecular response …
Imatinib could be safely discontinued in patients with a sustained deep molecular response …
[HTML][HTML] Achieving a complete molecular remission under imatinib therapy is associated with a better outcome in chronic phase chronic myeloid leukaemia patients on …
G Etienne, NE Nicolini, S Dulucq, A Schmitt, S Hayette… - Blood, 2012 - Elsevier
Abstract Abstract 3754 Background Imatinib (IM) has dramatically improved the prognosis of
chronic myeloid leukaemia (CML) patients. Some of them will achieve a so-call complete …
chronic myeloid leukaemia (CML) patients. Some of them will achieve a so-call complete …